Evotec-Almirall Team Advances Small Molecule Program to Preclinical Development
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 04 2026
0mins
Source: Yahoo Finance
- Rapid Development Progress: The collaboration between Evotec and Almirall has successfully nominated a small molecule preclinical development candidate within just two years, significantly outperforming standard industry timelines and showcasing Evotec's efficiency in drug discovery.
- Integrated Technology Advantage: The project leverages Evotec's AI/ML-driven R&D platforms, encompassing medicinal chemistry, DMPK, and in vitro biology, ensuring a seamless data-driven workflow that accelerates the candidate identification process.
- Market Demand Alignment: This initiative focuses on developing novel therapies for immune-mediated inflammatory skin diseases, addressing the urgent need for innovative treatment options in the market, which holds significant commercial potential.
- Strategic Partnership Value: The collaboration includes potential success-based milestone payments of up to €230 million, reflecting the deep expertise and shared goals of Evotec and Almirall in medical dermatology, indicating promising future success possibilities.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy EVO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on EVO
Wall Street analysts forecast EVO stock price to rise
3 Analyst Rating
2 Buy
0 Hold
1 Sell
Moderate Buy
Current: 2.720
Low
5.00
Averages
6.00
High
7.00
Current: 2.720
Low
5.00
Averages
6.00
High
7.00
About EVO
Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Evotec Announces Results of Annual General Meeting
- Voting Results: At Evotec SE's Annual General Meeting, all agenda items were adopted by shareholders with the required majority, demonstrating strong support and trust in the company's governance.
- New Supervisory Board Appointments: Shareholders elected Dieter Weinand and Dr. Wolfgang Hofmann to the Supervisory Board, with Weinand appointed as the new Chairman, succeeding Prof. Dr. Iris Löw-Friedrich, indicating a renewal and optimization of the company's governance structure.
- Board Member Re-elections: The re-election of Dr. Duncan McHale and Wesley Wheeler was approved by shareholders, ensuring continuity and accumulated experience within the Supervisory Board, which aids in the stable advancement of the company's strategy.
- Attendance Rate: The Annual General Meeting saw 43.10% of the registered share capital represented, reflecting high shareholder engagement and interest in the company's affairs.
See More
Evotec Issues €116.1M Convertible Bonds Due 2033
- Bond Issuance Size: Evotec SE successfully placed senior unsecured convertible bonds totaling €116.1 million on Tuesday, maturing in 2033, indicating strong market confidence in the company's financing needs.
- Bond Terms Details: The bonds are issued at a denomination of €100,000 each with an annual interest rate of 2.625%, payable semi-annually, reflecting the company's strategic focus on controlling financing costs.
- Investor Redemption Rights: Investors have the option to redeem the bonds after five years, with repayment at 110% of the principal at maturity, implying a yield to maturity of 3.882%, providing investors with a relatively stable return outlook.
- Clear Use of Proceeds: The company intends to utilize the net proceeds to support cash requirements for Project Horizon, aimed at strengthening its operating model and enabling sustained long-term value creation, demonstrating a clear strategic vision for future growth.
See More
European Stock Market Volatility and Undervalued Stocks Analysis
- Market Volatility Analysis: The European stock market has recently experienced volatility, with the pan-European STOXX Europe 600 Index posting modest gains as investor sentiment was buoyed by easing geopolitical tensions and strong corporate earnings, indicating a search for stability amidst uncertainty.
- Undervalued Stocks Identification: In the current market environment, identifying undervalued stocks is crucial, particularly those potentially trading below their intrinsic value, allowing investors to optimize their portfolios through these opportunities.
- SNGN Romgaz Financial Overview: SNGN Romgaz SA has a market cap of RON 52.03 billion, with full-year sales reaching RON 8.03 billion and net income at RON 3.35 billion in 2022, while projected annual growth of 10.9% indicates strong competitiveness in the Romanian market.
- Alleima Future Outlook: Alleima AB is currently trading at SEK 83.70, significantly below its estimated future cash flow value of SEK 112.76, and despite a decline in first-quarter sales to SEK 4.58 billion, it is expected to grow at an annual rate of 28%, far exceeding the Swedish market's average of 8.9%.
See More
Evotec-Almirall Team Advances Small Molecule Program to Preclinical Development
- Rapid Development Progress: The collaboration between Evotec and Almirall has successfully nominated a small molecule preclinical development candidate within just two years, significantly outperforming standard industry timelines and showcasing Evotec's efficiency in drug discovery.
- Integrated Technology Advantage: The project leverages Evotec's AI/ML-driven R&D platforms, encompassing medicinal chemistry, DMPK, and in vitro biology, ensuring a seamless data-driven workflow that accelerates the candidate identification process.
- Market Demand Alignment: This initiative focuses on developing novel therapies for immune-mediated inflammatory skin diseases, addressing the urgent need for innovative treatment options in the market, which holds significant commercial potential.
- Strategic Partnership Value: The collaboration includes potential success-based milestone payments of up to €230 million, reflecting the deep expertise and shared goals of Evotec and Almirall in medical dermatology, indicating promising future success possibilities.
See More
Evotec to Announce Q1 2026 Financial Results on May 6
- Earnings Announcement Schedule: Evotec SE will hold a webcast and conference call on May 6, 2026, to announce its Q1 2026 financial results and provide a business update, which is expected to attract significant attention from investors and analysts.
- Meeting Time and Format: The conference is scheduled for 2:00 PM CEST (12:00 PM GMT, 8:00 AM EDT), and participants must pre-register to receive dial-in details, ensuring smooth participation in the call.
- Company Background: Evotec is a life science company focused on drug discovery and development, leveraging breakthrough science and AI-driven innovation to accelerate the journey from concept to cure, showcasing strong market competitiveness.
- R&D Assets and Partnership Models: The company boasts over 100 proprietary R&D assets across key therapeutic areas such as oncology, cardiovascular, and metabolic diseases, and has established flexible partnership models with all Top 20 pharma companies and over 800 biotech firms, highlighting its significant position in the industry.
See More
Evotec CFO Paul Hitchin Resigns, Claire Hinshelwood Appointed
- Executive Change: Evotec SE announced that CFO Paul Hitchin will resign on April 30, citing personal reasons unrelated to the company, indicating potential challenges in executive stability.
- New Financial Chief: Claire Hinshelwood will take over as CFO on May 1, bringing over 30 years of financial leadership experience, particularly from her recent role as CFO at BMI Group, which is expected to introduce new financial strategies for the company.
- Stock Price Reaction: On Nasdaq, Evotec's shares rose 1.55% in after-hours trading to $3.28, reflecting market optimism regarding the new CFO's appointment, despite closing at $3.23 during regular trading.
- Market Confidence: Although executive changes can introduce uncertainty, the market's response suggests that investors maintain a positive outlook on Evotec's future financial management and strategic direction, which may influence its long-term stock performance.
See More
Evotec Announces Results of Annual General Meeting
- Voting Results: At Evotec SE's Annual General Meeting, all agenda items were adopted by shareholders with the required majority, demonstrating strong support and trust in the company's governance.
- New Supervisory Board Appointments: Shareholders elected Dieter Weinand and Dr. Wolfgang Hofmann to the Supervisory Board, with Weinand appointed as the new Chairman, succeeding Prof. Dr. Iris Löw-Friedrich, indicating a renewal and optimization of the company's governance structure.
- Board Member Re-elections: The re-election of Dr. Duncan McHale and Wesley Wheeler was approved by shareholders, ensuring continuity and accumulated experience within the Supervisory Board, which aids in the stable advancement of the company's strategy.
- Attendance Rate: The Annual General Meeting saw 43.10% of the registered share capital represented, reflecting high shareholder engagement and interest in the company's affairs.
See More
Evotec Issues €116.1M Convertible Bonds Due 2033
- Bond Issuance Size: Evotec SE successfully placed senior unsecured convertible bonds totaling €116.1 million on Tuesday, maturing in 2033, indicating strong market confidence in the company's financing needs.
- Bond Terms Details: The bonds are issued at a denomination of €100,000 each with an annual interest rate of 2.625%, payable semi-annually, reflecting the company's strategic focus on controlling financing costs.
- Investor Redemption Rights: Investors have the option to redeem the bonds after five years, with repayment at 110% of the principal at maturity, implying a yield to maturity of 3.882%, providing investors with a relatively stable return outlook.
- Clear Use of Proceeds: The company intends to utilize the net proceeds to support cash requirements for Project Horizon, aimed at strengthening its operating model and enabling sustained long-term value creation, demonstrating a clear strategic vision for future growth.
See More
European Stock Market Volatility and Undervalued Stocks Analysis
- Market Volatility Analysis: The European stock market has recently experienced volatility, with the pan-European STOXX Europe 600 Index posting modest gains as investor sentiment was buoyed by easing geopolitical tensions and strong corporate earnings, indicating a search for stability amidst uncertainty.
- Undervalued Stocks Identification: In the current market environment, identifying undervalued stocks is crucial, particularly those potentially trading below their intrinsic value, allowing investors to optimize their portfolios through these opportunities.
- SNGN Romgaz Financial Overview: SNGN Romgaz SA has a market cap of RON 52.03 billion, with full-year sales reaching RON 8.03 billion and net income at RON 3.35 billion in 2022, while projected annual growth of 10.9% indicates strong competitiveness in the Romanian market.
- Alleima Future Outlook: Alleima AB is currently trading at SEK 83.70, significantly below its estimated future cash flow value of SEK 112.76, and despite a decline in first-quarter sales to SEK 4.58 billion, it is expected to grow at an annual rate of 28%, far exceeding the Swedish market's average of 8.9%.
See More
Evotec-Almirall Team Advances Small Molecule Program to Preclinical Development
- Rapid Development Progress: The collaboration between Evotec and Almirall has successfully nominated a small molecule preclinical development candidate within just two years, significantly outperforming standard industry timelines and showcasing Evotec's efficiency in drug discovery.
- Integrated Technology Advantage: The project leverages Evotec's AI/ML-driven R&D platforms, encompassing medicinal chemistry, DMPK, and in vitro biology, ensuring a seamless data-driven workflow that accelerates the candidate identification process.
- Market Demand Alignment: This initiative focuses on developing novel therapies for immune-mediated inflammatory skin diseases, addressing the urgent need for innovative treatment options in the market, which holds significant commercial potential.
- Strategic Partnership Value: The collaboration includes potential success-based milestone payments of up to €230 million, reflecting the deep expertise and shared goals of Evotec and Almirall in medical dermatology, indicating promising future success possibilities.
See More
Evotec to Announce Q1 2026 Financial Results on May 6
- Earnings Announcement Schedule: Evotec SE will hold a webcast and conference call on May 6, 2026, to announce its Q1 2026 financial results and provide a business update, which is expected to attract significant attention from investors and analysts.
- Meeting Time and Format: The conference is scheduled for 2:00 PM CEST (12:00 PM GMT, 8:00 AM EDT), and participants must pre-register to receive dial-in details, ensuring smooth participation in the call.
- Company Background: Evotec is a life science company focused on drug discovery and development, leveraging breakthrough science and AI-driven innovation to accelerate the journey from concept to cure, showcasing strong market competitiveness.
- R&D Assets and Partnership Models: The company boasts over 100 proprietary R&D assets across key therapeutic areas such as oncology, cardiovascular, and metabolic diseases, and has established flexible partnership models with all Top 20 pharma companies and over 800 biotech firms, highlighting its significant position in the industry.
See More
Evotec CFO Paul Hitchin Resigns, Claire Hinshelwood Appointed
- Executive Change: Evotec SE announced that CFO Paul Hitchin will resign on April 30, citing personal reasons unrelated to the company, indicating potential challenges in executive stability.
- New Financial Chief: Claire Hinshelwood will take over as CFO on May 1, bringing over 30 years of financial leadership experience, particularly from her recent role as CFO at BMI Group, which is expected to introduce new financial strategies for the company.
- Stock Price Reaction: On Nasdaq, Evotec's shares rose 1.55% in after-hours trading to $3.28, reflecting market optimism regarding the new CFO's appointment, despite closing at $3.23 during regular trading.
- Market Confidence: Although executive changes can introduce uncertainty, the market's response suggests that investors maintain a positive outlook on Evotec's future financial management and strategic direction, which may influence its long-term stock performance.
See More
